Abstract: Platelet cell data may be obtained from analysis of a blood sample by a hematology analyzer or like device. Systems and apparatus may process the platelet cell data in accordance with platelet parameter thresholds selected by a user. The platelet cell data may then be categorized and displayed in one or more useful forms for medical diagnostic and/or research purposes. The platelet cell data may be categorized and displayed in, e.g., tabular and/or graphical form based on the user-selected platelet parameter thresholds. Methods of processing platelet cell data for categorizing and displaying the platelet cell data in one or more useful forms are also provided, as are other aspects.

Abstract: Platelet cell data may be obtained from analysis of a blood sample by a hematology analyzer or like device. Systems and apparatus may process the platelet cell data in accordance with platelet parameter thresholds selected by a user. The platelet cell data may then be categorized and displayed in one or more useful forms for medical diagnostic and/or research purposes. The platelet cell data may be categorized and displayed in, e.g., tabular and/or graphical form based on the user-selected platelet parameter thresholds. Methods of processing platelet cell data for categorizing and displaying the platelet cell data in one or more useful forms are also provided, as are other aspects.

Abstract: A modified human acid alpha-glucosidase polypeptide is provided, as well as methods of making and using modified human acid alpha-glucosidase to treat glycogen storage disorders.

Abstract: Embodiments of the methods and systems of the present invention may provide improved methods for the verification of an integrated circuit where a verification project for an integrated circuit may be created by selecting a set of intent units corresponding to the integrated circuit design from a library of intent units and linking these intent units to the integrated circuit design. Specifically, in one embodiment each of these intent units may comprise a corresponding code component and text component such that from the set of intent units selected and configured based on the integrated circuit design a verification plan can be generated from the text components of the corresponding intent units while a testbench can be generated from the code components of the corresponding intent units. This testbench can then be used to generate a model for testing the integrated circuit design.

Abstract: The present invention provides methods of producing a pro-N-acetylglucosamine-1-phosphodiester?N-acetyl glucosimanidase (phosphodiester ?-GlcNAcase), in mammalian cells deficient in the furin proteolytic enzyme and methods of making lysosomal bydrolases having an N-acetylglucosamine-1-phosphate.

Abstract: The present invention provides nucleotide and amino sequences of the lysosomal targeting pathway enzyme GlcNAc-phosphotransferase, methods of producing and methods of purifying this enzyme.

Abstract: The present invention relates to a soluble GlcNAc phosphotransferase, a method of making the same and a method of phosphorylating with the same.

Abstract: The present invention relates to a soluble GlcNAc phosphotransferase, a method of making the same and a method of phosphorylating with the same.

Abstract: The present invention provides nucleotide and amino sequences of the lysosomal targeting pathway enzyme GlcNAc-phosphotransferase, methods of producing and methods of purifying this enzyme.

Abstract: A folding modular structure is described. The structure typically includes a top panel, which is ultimately the roof deck. Two side panels, a front and a rear panel are connected to the top panel by pivoting mechanisms so that the side, front and rear panels can fold open to create the modular structure. Spacer panels are connected between three of the four total side, front and rear panels. The spacer panels are necessary to provide clearance so that each of the panels can be folded onto the other already folded panels. In the folded configuration, shipping many more modular structures to final destinations is possible.

Abstract: The present invention provides methods of producing a pro-N-acetylglucosamine-1-phosphodiester ? N-acetyl glucosimanidase (phosphodiester ?-GlcNAcase), in mammalian cells deficient in the furin proteolytic enzyme and methods of making lysosomal bydrolases having an N-acetylglucosamine-1-phosphate.

Abstract: A military command and control system includes functional portions which respond to a set of or plurality of commands. Certain commands are mandatory. Specific responses are made in response to the mandatory commands. System tracks are handled differently than local tracks. Command and control systems which use the mandatory command structure are more readily upgraded than prior-art integrated command and control systems.

Abstract: A military command and control system includes functional portions which respond to a set of or plurality of commands. Certain commands are mandatory. Specific responses are made in response to the mandatory commands. System tracks are handled differently than local tracks. Command and control systems which use the mandatory command structure are more readily upgraded than prior-art integrated command and control systems.

Abstract: The present invention provides methods of producing a pro-N-acetylglucosamine-1-phosphodiester &agr; N-acetyl glucosimanidase (phosphodiester &agr;-GlcNAcase), in mammalian cells deficient in the furin proteolytic enzyme and methods of making lysosomal hydrolases having an N-acetylglucosamine-1-phosphate.

Abstract: The present invention provides methods of producing a pro-N-acetylglucosamine-1-phosphodiester &agr; N-acetyl glucosimanidase (phosphodiester &agr;-GlcNAcase), in mammalian cells deficient in the furin proteolytic enzyme and methods of making lysosomal hydrolases having an N-acetylglucosamine-1-phosphate.

Abstract: The present invention provides a highly phosphorylated acid beta-glucocerebrosidase (GBA), which can be employed in an enzyme replacement therapy protocol to treat patients suffering from Gaucher's disease.

Abstract: The present invention relates to a soluble GlcNAc phosphotransferase, a method of making the same and a method of phosphorylating with the same.